Rena M. Conti, PhD


Value in Cancer Care: An Economist's Perspective

May 10, 2016

Measuring the quality of oncology care and associating it with reimbursement, and high drug prices remain important concerns of value-based outpatient cancer care. A healthcare economist reviews the current status and suggests a potential path forward.

Three Proposals to Reform the 340B Drug Discount Program

December 10, 2015

The 340B Drug Discount Program has rapidly expanded over the last few years and may be missing its original intent. Here are 3 possible steps that could enhance the program’s function and mirror Congress’ original intent to enhance access for the poor to essential medical services.

Infused Chemotherapy Use in the Elderly After Patent Expiration

May 09, 2012

As calls for improving the quality and cost efficiency of oncology increase, future empirical work is needed to examine the responsiveness of oncologists' treatment decision making to incentives among patients of all ages and insurance types.